BCAB

Bioatla Inc

Add to Watchlist

Advanced Chart

0.456

+0.036(8.571%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

0.4558

Open

0.430

VWAP

0.44

Vol

686.83K

Mkt Cap

26.75M

Low

0.4103

Amount

299.79K

EV/EBITDA(TTM)

Total Shares

48.12M

6.46M

EV/OCF(TTM)

P/S(TTM)

BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

-0.295

+13.46%

-0.303

+1.11%

-0.297

+34.85%

Estimates Revision

The market is revising No Change the revenue expectations for BioAtla, Inc. (BCAB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 16.50%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+16.50%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast BCAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCAB is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

2 Hold

0 Sell

Hold

Current: 0.456

Low

10.00

Averages

10.00

High

10.00

Current: 0.456

Low

10.00

Averages

10.00

High

10.00

Citizens JMP

Reni Benjamin

Outperform -> Market Perform

downgrade

$NULL

2025-08-13

Reason

Citizens JMP

Reni Benjamin

Price Target

$NULL

2025-08-13

downgrade

Outperform -> Market Perform

Reason

Citizens JMP analyst Reni Benjamin downgraded BioAtla to Market Perform from Outperform without a price target following the Q2 report. The firm views the shares as fairly valued given expecatatations for no revenue or earnings in the near future. BioAtla is facing an evolving landscape and uncertainty regarding a potential partnership, the analyst tells investors in a research note. With a partnership, Citizens views the company's current cash position as insufficient to sustain operations.

HC Wainwright & Co.

Arthur He

Hold

Reiterates

n/a

2025-03-31

Reason

HC Wainwright & Co.

Arthur He

Price Target

n/a

2025-03-31

Reiterates

Hold

Reason

Citizens Capital Markets

Reni Benjamin

Buy

Maintains

$5 → $1

2025-03-31

Reason

Citizens Capital Markets

Reni Benjamin

Price Target

$5 → $1

2025-03-31

Maintains

Buy

Reason

Citizens JMP analyst Reni Benjamin lowered the firm's price target on BioAtla to $1 from $5 and keeps an Outperform rating on the shares following the Q4 report. With initial data for BA3182 expected in mid-2025, three other assets seeking potential partnership opportunities, and a cash position of $49M, the shares could rebound if we see some "interesting data" with the T cell engaging asset or a potential partner provides non-dilutive capital, the analyst tells investors in a research note. Citizens believes there is an "asymmetric risk setup towards the upside, if any of the ongoing partnership discussions materialize."

HC Wainwright & Co.

Arthur He

Strong Buy

Hold

Downgrades

n/a

2024-11-13

Reason

HC Wainwright & Co.

Arthur He

Price Target

n/a

2024-11-13

Downgrades

Strong Buy

Hold

Reason

JMP Securities

Reni Benjamin

Buy

Reiterates

2024-09-16

Reason

JMP Securities

Reni Benjamin

Price Target

2024-09-16

Reiterates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Bioatla Inc (BCAB.O) is -0.36, compared to its 5-year average forward P/E of -4.53. For a more detailed relative valuation and DCF analysis to assess Bioatla Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.53

Current PE

-0.36

Overvalued PE

2.17

Undervalued PE

-11.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.96

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

3.16

Undervalued EV/EBITDA

-9.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

80.74

Current PS

0.00

Overvalued PS

192.35

Undervalued PS

-30.87

Financials

Annual

Quarterly

FY2025Q2

N/A

Total Revenue

FY2025Q2

YoY :

-15.13%

-18.65M

Operating Profit

FY2025Q2

YoY :

-11.20%

-18.71M

Net Income after Tax

FY2025Q2

YoY :

-27.27%

-0.32

EPS - Diluted

FY2025Q2

YoY :

-100.00%

N/A

Free Cash Flow

FY2025Q2

N/A

Gross Profit Margin - %

FY2025Q2

N/A

FCF Margin - %

FY2025Q2

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 760.39% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

1.4M

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

686.4K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

BCAB News & Events

Events Timeline

2025-07-03 (ET)

2025-07-03

08:04:19

BioAtla presents data from ongoing dose escalation fo BA3182

2025-06-02 (ET)

2025-06-02

08:22:57

BioAtla presents Phase 2 Oz-V clinical trial data at ASCO 2025

2025-05-06 (ET)

2025-05-06

17:24:35

BioAtla files to sell 9.68M shares of common stock for holders

News

9.5

08-07NASDAQ.COM

BioAtla (BCAB) Q2 Loss Narrows 27%

9.0

07-03Newsfilter

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress

9.5

04-29Yahoo Finance

BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025